11.28.16
Patheon, a global provider of drug development and delivery services to the pharma and biopharma industries, has signed a definitive agreement to acquire an API manufacturing facility in Florence, SC, from Roche Holdings, Inc., for an undisclosed sum, plus the cost of associated inventory and spare parts. Patheon has also entered into a multi-year supply arrangement with Roche, the details of which were not disclosed.
The 300,000 sq.-ft. facility has manufacturing capacity for API ranging from development to manufacturing services, expanding the company’s capacity for manufacturing highly potent compounds and adding capabilities to support solid-state chemistry, micronization, and eventually, commercial spray drying.
The site has reactors ranging from 50 -11,000 liters producing multiple products simultaneously, and is compliant with regulations, such as cGMP safety and environmental standards. It will provide Patheon with a major U.S. API operation to support products from clinical scale to commercial manufacturing.
“As the only end-to-end provider of pharma development and manufacturing services, Patheon is uniquely positioned to integrate this new site into our global network and quickly leverage the capabilities with existing and new clients,” said James Mullen, chief executive officer of Patheon. “The company will benefit from the additional North American API capacity and adds a state-of-the-art facility with approximately 200 scientific and manufacturing professionals.”
The 300,000 sq.-ft. facility has manufacturing capacity for API ranging from development to manufacturing services, expanding the company’s capacity for manufacturing highly potent compounds and adding capabilities to support solid-state chemistry, micronization, and eventually, commercial spray drying.
The site has reactors ranging from 50 -11,000 liters producing multiple products simultaneously, and is compliant with regulations, such as cGMP safety and environmental standards. It will provide Patheon with a major U.S. API operation to support products from clinical scale to commercial manufacturing.
“As the only end-to-end provider of pharma development and manufacturing services, Patheon is uniquely positioned to integrate this new site into our global network and quickly leverage the capabilities with existing and new clients,” said James Mullen, chief executive officer of Patheon. “The company will benefit from the additional North American API capacity and adds a state-of-the-art facility with approximately 200 scientific and manufacturing professionals.”
